K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting compone...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Irmgard, Weiss, Andreas, Elain, Gaelle, Schwaederle, Maria, Sterker, Dario, Romanet, Vincent, Schmelzle, Tobias, Lai, Albert, Brachmann, Saskia M., Bentires-Alj, Mohamed, Roberts, Thomas M., Sellers, William R., Hofmann, Francesco, Maira, Sauveur-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432074/
https://www.ncbi.nlm.nih.gov/pubmed/22952903
http://dx.doi.org/10.1371/journal.pone.0044146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432074/
https://www.ncbi.nlm.nih.gov/pubmed/22952903
http://dx.doi.org/10.1371/journal.pone.0044146

Ejemplares similares